BioNotebook: Seragon, Arcturus, Seattle Genetics, Cytos, CIRM
This article was originally published in Scrip
Executive Summary
Seragon announces Series A funding amount; Arcturus raises $5m Series A; Seattle Genetics enters clinic with new ADC; Cytos earns Phase IIb cash; and CIRM president steps down.